FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION
20170298030 · 2017-10-19
Inventors
- Raghavan Rajagopalan (Solon, OH)
- Richard B. Dorshow (St. Louis, MO)
- William L. Neumann (St. Louis, MO)
- Dennis A. Moore (St. Louis, MO)
Cpc classification
A61K49/0004
HUMAN NECESSITIES
A61K49/0021
HUMAN NECESSITIES
C07D241/26
CHEMISTRY; METALLURGY
International classification
C07D241/28
CHEMISTRY; METALLURGY
C07D241/26
CHEMISTRY; METALLURGY
Abstract
The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. X.sup.1 to X.sup.4 of Formulas I and II may be characterized as electron withdrawing groups, while Y.sup.1 to Y.sup.4 of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing organ (e.g., kidney) function. In a particular example, an effective amount of a pyrazine derivative that is capable of being renally cleared may be administered into a patient's body. The pyrazine derivative may capable of one or both absorbing and emanating spectral energy of at least about 400 nm (e.g., visible and/or infrared light). At least some of the derivative that is in the body may be exposed to spectral energy and, in turn, spectral energy may emanate from the derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.
##STR00001##
Claims
1.-8. (canceled)
9. The compound of Formula II, wherein: ##STR00029## each of X.sup.3 and X.sup.4 is independently selected from the group consisting of —CN, —CO.sub.2R.sup.20, —CONR.sup.21R.sup.22, —COR.sup.23, —NO.sub.2, —SOR.sup.24, —SO.sub.2R.sup.25, —SO.sub.2OR.sup.26 and —PO.sub.3R.sup.27R.sup.28. each of Y.sup.3 and Y.sup.4 is independently selected from the group consisting of —OR.sup.29, —SR.sup.30, —NR.sup.31R.sup.32, —N(R.sup.33)COR.sup.34 and ##STR00030## Z.sup.2 is selected from the group consisting of a direct bond, —CR.sup.35R.sup.36—, —O—, —NR.sup.37—, —NCOR.sup.38—, —S—, —SO— and —SO.sub.2.sup.−; each of R.sup.20 to R.sup.38 is independently selected from the group consisting of hydrogen, C3-C6 polyhydroxylated alkyl, —((CH.sub.2).sub.2—O—(CH.sub.2).sub.2—O).sub.b—R.sup.40, C1-C10 alkyl, C5-C10 aryl, C5-C10 heteroaryl, —(CH.sub.2).sub.bOH, —(CH.sub.2).sub.bCO.sub.2H, —(CH.sub.2).sub.bSO.sub.3H, —(CH.sub.2).sub.bSO.sub.3.sup.−, —(CH.sub.2).sub.bOSO.sub.3H, —(CH.sub.2).sub.bOSO.sub.3.sup.−, —(CH.sub.2).sub.bNHSO.sub.3H, —(CH.sub.2).sub.bNHSO.sub.3.sup.−, —(CH.sub.2).sub.bPO.sub.3H.sub.2, —(CH.sub.2).sub.bPO.sub.3H.sup.−, —(CH.sub.2).sub.bPO.sub.3.sup.═, —(CH.sub.2).sub.bOPO.sub.3H.sub.2, —(CH.sub.2).sub.bOPO.sub.3H.sup.− and —(CH.sub.2).sub.bOPO.sub.3.sup.═; R.sup.40 is selected from the group consisting of hydrogen, C1-C10 alkyl, C5-C10 aryl, C5-C10 heteroaryl, —(CH.sub.2).sub.bOH, —(CH.sub.2).sub.bCO.sub.2H, —(CH.sub.2).sub.bSO.sub.3H, —(CH.sub.2).sub.bSO.sub.3.sup.−, —(CH.sub.2).sub.bOSO.sub.3H, —(CH.sub.2).sub.bOSO.sub.3.sup.−, —(CH.sub.2).sub.bNHSO.sub.3H, —(CH.sub.2).sub.bNHSO.sub.3.sup.−, —(CH.sub.2).sub.bPO.sub.3H.sub.2, —(CH.sub.2).sub.bPO.sub.3H.sup.−, —(CH.sub.2).sub.bPO.sub.3.sup.═, —(CH.sub.2).sub.bOPO.sub.3H.sub.2, —(CH.sub.2).sub.bOPO.sub.3H′ and —(CH.sub.2).sub.bOPO.sub.3.sup.═; and b, p and q range from 1 to 6; with the proviso that if: each of X.sup.3 and X.sup.4 is independently —CN, —CO.sub.2R.sup.20 or —CONR.sup.21R.sup.22; each of Y.sup.3 and Y.sup.4 is independently —NR.sup.31R.sup.32, or ##STR00031## and Z.sup.2 is a direct bond, then: each of R.sup.20, R.sup.21, R.sup.22, R.sup.31 and R.sup.32 is independently not hydrogen, C1-C10 alkyl or C1-C10 aryl; and p, q, N and Z.sup.2 together do not form a 5- or 6-membered ring.
10. The compound of claim 9 wherein: each of X.sup.3 and X.sup.4 is selected from the group consisting of —CN, —CO.sub.2R.sup.20 and —CONR.sup.21R.sup.22; each of Y.sup.3 and Y.sup.4 is independently —NR.sup.31R.sup.32 or ##STR00032## each of R.sup.20, R.sup.21, R.sup.22, R.sup.31 and R.sup.32 is independently selected from the group consisting of C3-C6 polyhydroxylated alkyl, —((CH.sub.2).sub.2—O—(CH.sub.2).sub.2—O).sub.b—R.sup.40, C5-C10 heteroaryl, —(CH.sub.2).sub.bOH, —(CH.sub.2).sub.bCO.sub.2H, —(CH.sub.2)b.sub.aSO.sub.3H and —(CH.sub.2)b.sub.aSO.sub.3.sup.−; each of R.sup.35 to R.sup.38 is independently selected from the group consisting of hydrogen, C3-C6 polyhydroxylated alkyl, —((CH.sub.2).sub.2—O—(CH.sub.2).sub.2—O).sub.b—R.sup.40, C1-C10 alkyl, C5-C10 aryl, C5 to C10 heteroaryl, —(CH.sub.2).sub.bOH, —(CH.sub.2).sub.bCO.sub.2H, —(CH.sub.2).sub.bSO.sub.3H and —(CH.sub.2).sub.bSO.sub.3.sup.−; p is 1 or 2; and q is 1.
11. The compound of claim 10 wherein: each of X.sup.3 and X.sup.4 is —CN; Z.sup.2 is selected from the group consisting of a direct bond, —O—, —NR.sup.37—, —NCOR.sup.38—, —S—, —SO— and —SO.sub.2—; each of R.sup.31 and R.sup.32 is independently selected from the group consisting of C3-C6 polyhydroxylated alkyl, —((CH.sub.2).sub.2—O—(CH.sub.2).sub.2—O).sub.b—R.sup.40, —(CH.sub.2).sub.bOH, —(CH.sub.2).sub.bCO.sub.2H, —(CH.sub.2).sub.bSO.sub.3H and —(CH.sub.2).sub.bSO.sub.3.sup.−; and each of R.sup.37 and R.sup.38 is independently selected from the group consisting of hydrogen, C3-C6 polyhydroxylated alkyl, —((CH.sub.2).sub.2—O—(CH.sub.2).sub.2—O).sub.b—R.sup.40, C1-C10 alkyl, —(CH.sub.2).sub.bOH, —(CH.sub.2).sub.bCO.sub.2H, —(CH.sub.2).sub.bSO.sub.3H and —(CH.sub.2).sub.bSO.sub.3.sup.−.
12. The compound of claim 11 wherein: each of Y.sup.3 and Y.sup.4 is —NR.sup.31R.sup.32; and each of R.sup.31 and R.sup.32 is —(CH.sub.2).sub.bCO.sub.2H.
13. The compound of claim 11 wherein: each of Y.sup.3 and Y.sup.4 is ##STR00033##
14. The compound of claim 10 wherein: each of X.sup.3 and X.sup.4 is —CO.sub.2R.sup.20; Z.sup.2 is selected from the group consisting of a direct bond, —O—, —NR.sup.37—, —NCOR.sup.38—, —S—, —SO— and —SO.sub.2—; R.sup.20 is hydrogen; each of R.sup.31 and R.sup.32 is independently selected from the group consisting of C3-C6 polyhydroxylated alkyl, —((CH.sub.2).sub.2—O—(CH.sub.2).sub.2—O).sub.b—R.sup.40, —(CH.sub.2).sub.bOH, —(CH.sub.2).sub.bCO.sub.2H, —(CH.sub.2).sub.bSO.sub.3H and —(CH.sub.2).sub.bSO.sub.3—; and each of R.sup.37 and R.sup.38 is independently selected from the group consisting of hydrogen, C3-C6 polyhydroxylated alkyl, —((CH.sub.2).sub.2—O—(CH.sub.2).sub.2—O).sub.b—R.sup.40, C1-C10 alkyl, —(CH.sub.2).sub.bOH, —(CH.sub.2).sub.bCO.sub.2H, —(CH.sub.2).sub.bSO.sub.3H and —(CH.sub.2).sub.bSO.sub.3.sup.−.
15. The compound of claim 14 wherein: each of Y.sup.3 and Y.sup.4 is —NR.sup.31R.sup.32; and each of R.sup.31 and R.sup.32 is —(CH.sub.2).sub.bCO.sub.2H.
16. The compound of claim 14 wherein each of Y.sup.3 and Y.sup.4 is ##STR00034##
17.-44. (canceled)
Description
BRIEF DESCRIPTION OF THE FIGURES
[0016]
[0017]
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
DETAILED DESCRIPTION OF VARIOUS EMBODIMENTS
[0024] The present invention discloses renal function monitoring compounds. An example of a particular compound of the invention corresponds to Formula I below. In this exemplary embodiment, X.sup.1 and X.sup.2 are electron withdrawing substituents independently chosen from the group consisting of —CN, —CO.sub.2R.sup.1, —CONR.sup.2R.sup.3, —COR.sup.4, —NO.sub.2, —SOR.sup.5, —SO.sub.2R.sup.6, —SO.sub.2OR.sup.7 and —PO.sub.3R.sup.8R.sup.9. Y.sup.1 and Y.sup.2 are independently chosen from the group consisting of —OR.sup.10, —SR.sup.11, —NR.sup.12R.sup.13, —N(R.sup.4)COR.sup.15 and substituents represented by Formula A. Z.sup.1 is selected from the group consisting of a direct bond, —CR.sup.16R.sup.17—, —O—, —NR.sup.18—, —NCOR.sup.19—, —S—, —SO— and —SO.sub.2—. Each of the R groups of R.sup.1 to R.sup.19 are independently selected from the group consisting of hydrogen, C3-C6 polyhydroxylated alkyl, —((CH.sub.2).sub.2—O—(CH.sub.2).sub.2—O).sub.aR.sup.40, C1-C10 alkyl, C5-C10 aryl, C5-C10 heteroaryl, —(CH.sub.2).sub.aOH, —(CH.sub.2).sub.aCO.sub.2H, —(CH.sub.2).sub.aSO.sub.3H, —(CH.sub.2).sub.aSO.sub.3.sup.−, —(CH.sub.2).sub.aOSO.sub.3H, —(CH.sub.2).sub.aOSO.sub.3.sup.−, —(CH.sub.2).sub.aNHSO.sub.3H, —(CH.sub.2).sub.aNHSO.sub.3.sup.−, —(CH.sub.2).sub.aPO.sub.3H.sub.2, —(CH.sub.2).sub.aPO.sub.3H.sup.−, —(CH.sub.2).sub.aPO.sub.3.sup.−, (CH.sub.2).sub.aOPO.sub.3H.sub.2, —(CH.sub.2)OPO.sub.3H.sup.− and —(CH.sub.2).sub.aOPO.sub.3. R.sup.40 is selected from the group consisting of hydrogen, C1-C10 alkyl, C5-C10 aryl, C5-C10 heteroaryl, —(CH.sub.2).sub.aOH, —(CH.sub.2).sub.aCO.sub.2H, —(CH.sub.2).sub.aSO.sub.3H.sup.−, —(CH.sub.2)SO.sub.3, —(CH.sub.2).sub.aOSO.sub.3H, —(CH.sub.2).sub.aOSO.sub.3, —(CH.sub.2).sub.aNHSO.sub.3H, —(CH.sub.2).sub.aNHSO.sub.3.sup.−, —(CH.sub.2).sub.aPO.sub.3H.sub.2, —(CH.sub.2).sub.aPO.sub.3H.sup.−, —(CH.sub.2).sub.aPO.sub.3.sup.−, —(CH.sub.2).sub.aOPO.sub.3H.sub.2, —(CH.sub.2).sub.aOPO.sub.3H.sup.− and —(CH.sub.2).sub.aOPO.sub.3. “m” and “n” independently fall within the range of 1 to 6 inclusive in some embodiments, and independently fall within the range of 1 to 3 inclusive in some embodiments. “a” is an integer from 1 to 10 inclusive in some embodiments, and is an integer from 1 to 6 inclusive in some embodiments.
[0025] In some embodiments represented by Formula I, each of X.sup.1 and X.sup.2 are —CN, —CO.sub.2R.sup.1 or —CONR.sup.2R.sup.3, each of Y.sup.1 and Y.sup.2 are —NR.sup.12R.sup.13 or the substituent of Formula A, and Z.sup.1 is a direct bond. In such compositions, each of R.sup.1, R.sup.2, R.sup.3, R.sup.12 and R.sup.13 is not hydrogen, C1-C10 alkyl or C1-C10 aryl, and m, n, N and Z.sup.1 together do not form a 5- or 6-membered ring.
##STR00004##
[0026] In some embodiments represented by Formula I, X.sup.1 and X.sup.2 are independently selected from the group consisting of —CN, —CO.sub.2R.sup.1, —CONR.sup.2R.sup.3, —SO.sub.2R.sup.6 and —SO.sub.2OR.sup.7. Further, Y.sup.1 and Y.sup.2 are independently selected from the group consisting of —NR.sup.12R.sup.13, —N(R.sup.14)COR.sup.is and substituents represented by Formula A. Z.sup.1 is selected from the group consisting of a direct bond, —CR.sup.16R.sup.17—, —O—, —NR.sup.18—, —NCOR.sup.19—, —S—, —SO— and —SO.sub.2—. The R groups of R.sup.1 to R.sup.19 are each independently selected from the group consisting of hydrogen, C3-C6 polyhydroxylated alkyl, —((CH.sub.2).sub.2—O—(CH.sub.2).sub.2—O).sub.a—R.sup.40, C1-C10 alkyl, C5-C10 heteroaryl, C5-C10 aryl, —(CH.sub.2).sub.aOH, —(CH.sub.2).sub.aCO.sub.2H, —(CH.sub.2).sub.aSO.sub.3H and —(CH.sub.2).sub.aSO.sub.3.sup.−. Further, “a”, “m” and “n” fall within a range from 1 to 3 inclusive.
[0027] In some embodiments represented by Formula I, X.sup.1 and X.sup.2 are independently chosen from the group consisting of —CN, —CO.sub.2R.sup.1 and —CONR.sup.2R.sup.3. Y.sup.1 and Y.sup.2 are independently selected from the group consisting of —NR.sup.2R.sup.13 and substituents represented by Formula A. Z.sup.1 is selected from the group consisting of a direct bond, —CR.sup.16R.sup.17—, —O—, —NR.sup.18—, —NCOR.sup.9—, —S—, —SO— and —SO.sub.2—. Each of the R groups of R.sup.1 to R.sup.19 is independently selected from the group consisting of hydrogen, C3-C6 polyhydroxylated alkyl, —((CH.sub.2).sub.2—O—(CH.sub.2).sub.2—O).sub.a—R.sup.4, C1-C10 alkyl, —(CH.sub.2).sub.aOH and —(CH.sub.2).sub.aCO.sub.2H. Further, “a,” “m” and “n” are within a range from 1 to 3 inclusive.
[0028] Another example of a particular compound of the invention corresponds to Formula II below.
[0029] In this exemplary embodiment, X.sup.3 and X.sup.4 are electron withdrawing substituents independently selected from the group consisting of —CN, —CO.sub.2R.sup.20, —CONR.sup.21R.sup.22, —COR.sup.23, —NO.sub.2, —SOR.sup.24, —SO.sub.2R.sup.25, —SO.sub.2OR.sup.26 and —PO.sub.3R.sup.27R.sup.28. Y.sup.3 and Y.sup.4 are electron donating substituents independently selected from the group consisting of —OR.sup.29, —SR.sup.30, —NR.sup.31R.sup.32, —N(R.sup.33)COR.sup.34 and substituents represented by Formula B. Z.sup.2 is selected from the group consisting of a direct bond, —CR.sup.35R.sup.36—, —O—, —NR.sup.37—, —NCOR.sup.38—, —S—, —SO—, and —SO.sub.2—. Each of the R groups of R.sup.20 to R.sup.38 are independently selected from the group consisting of hydrogen, C3-C6 polyhydroxylated alkyl, —((CH.sub.2).sub.2—O—(CH.sub.2).sub.2—O).sub.b—R.sup.40, C1-C10 alkyl, C5-C10 aryl, C5-C10 heteroaryl, —(CH.sub.2).sub.bOH, —(CH.sub.2).sub.bCO.sub.2H, —(CH.sub.2).sub.bSO.sub.3H, —(CH.sub.2).sub.bSO.sub.3.sup.−, —(CH.sub.2).sub.bOSO.sub.3H, —(CH.sub.2).sub.bOSO.sub.3.sup.−, —CH.sub.2).sub.bNHSO.sub.3H, —(CH.sub.2).sub.bNHSO.sub.3.sup.−, —(CH.sub.2).sub.bPO.sub.3H.sub.2, —(CH.sub.2).sub.bPO.sub.3H, —(CH.sub.2).sub.bPO.sub.3.sup.−, —(CH.sub.2).sub.bOPO.sub.3H.sub.2, —(CH.sub.2).sub.bOPO.sub.3H and —(CH.sub.2).sub.bOPO.sub.3. R.sup.40 is selected from the group consisting of hydrogen, C1-C10 alkyl, C5-C10 aryl, C5-C10 heteroaryl, —(CH.sub.2).sub.bOH, —(CH.sub.2).sub.bCO.sub.2H, —(CH.sub.2).sub.bSO.sub.3H, —(CH.sub.2).sub.bSO.sub.3.sup.−, —(CH.sub.2).sub.bOSO.sub.3H, —(CH.sub.2).sub.bOSO.sub.3.sup.−, —(CH.sub.2).sub.bNHSO.sub.3H, —(CH.sub.2).sub.bNHSO.sub.3.sup.−, —(CH.sub.2).sub.bPO.sub.3H.sub.2, —(CH.sub.2).sub.bPO.sub.3H.sup.−, —(CH.sub.2).sub.bPO.sub.3.sup.−, —(CH.sub.2).sub.bOPO.sub.3H.sub.2, —(CH.sub.2).sub.bOPO.sub.3H.sup.− and —(CH.sub.2).sub.bOPO.sub.3. “p” and “q” independently fall within the range of 1 to 6 inclusive in some embodiments, and independently fall within the range of 1 to 3 inclusive in some embodiments. “b” is an integer from 1 to 10 inclusive in some embodiments, and is an integer from 1 to 6 inclusive in some embodiments.
[0030] In some embodiments represented by Formula II, X.sup.3 and X.sup.4 are independently —CN, —CO.sub.2R.sup.20 or —CONR.sup.21R.sup.22; Y.sup.3 and Y.sup.4 are independently —NR.sup.31R.sup.32 or a substituent of Formula B; and Z.sup.2 is a direct bond. In such embodiments, each of R.sup.20, R.sup.21, R.sup.22, R.sup.31 and R.sup.32 is independently not hydrogen, C3-C6 polyhydroxylated alkyl, —((CH.sub.2).sub.2—O—(CH.sub.2).sub.2—O).sub.b—R.sup.40, C1-C10 alkyl or C1-C10 aryl. Further, p, q, N and Z.sup.2 together do not form a 5- or 6-membered ring in such embodiments.
##STR00005##
[0031] In some embodiments represented by Formula II, X.sup.3 and X.sup.4 are independently selected from the group consisting of —CN, —CO.sub.2R.sup.20, —CONR.sup.21R.sup.22, —SO.sub.2R.sup.25 and —SO.sub.2R.sup.26. Y.sup.3 and Y.sup.4 are independently selected from the group consisting of —NR.sup.31R.sup.32, —N(R.sup.33)COR.sup.34 and substituents represented by Formula B. Z.sup.2 is selected from the group consisting of a direct bond, —CR.sup.35R.sup.36—, —O—, —NR.sup.37—, —NCOR.sup.38—, —S—, —SO— and —SO.sub.2—. Each of the R groups of R.sup.20 to R.sup.38 are independently selected from the group consisting of hydrogen, C3-C6 polyhydroxylated alkyl, —((CH.sub.2).sub.2—O—(CH.sub.2).sub.2—O).sub.b—R.sup.40, C1-C10 alkyl, C5-C10 aryl, C5-C10 heteroaryl —(CH.sub.2).sub.bOH, —(CH.sub.2).sub.bCO.sub.2H, —(CH.sub.2).sub.bSO.sub.3H and —(CH.sub.2).sub.bSO.sub.3.sup.−. In these embodiments, “b”, “p” and “q” independently range from 1 to 3 inclusive.
[0032] Some embodiments represented by Formula II have X.sup.3 and X.sup.4 being independently selected from the group consisting of —CN, —CO.sub.2R.sup.20 and —CONR.sup.21R.sup.22. Each of Y.sup.3 and Y.sup.4 may be —NR.sup.33R.sup.34 or a substituent represented by Formula B. Z.sup.2 is selected from the group consisting of a direct bond, —CR.sup.16R.sup.17, —O, —NR.sup.18, —NCOR.sup.19, —S, —SO and —SO.sub.2. R.sup.20 to R.sup.38 are independently selected from the group consisting of hydrogen, C3-C6 polyhydroxylated alkyl, —((CH.sub.2).sub.2—O—(CH.sub.2).sub.2—O).sub.b—R.sup.40, C1-C10 alkyl, —(CH.sub.2).sub.bOH and —(CH.sub.2).sub.aCO.sub.2H. “b”, “p” and “q” independently range from 1 to 3 inclusive.
[0033] By way of example, and not by way of limitation, compounds of Formula I and Formula II include the following (other exemplary compounds include those described in Examples 1-16):
##STR00006## ##STR00007##
[0034] Syntheses of pyrazine derivatives, in general, has been previously studied [27] and described [25, 26, 28, 29]. Preparation procedures for at least some of the pyrazine derivatives disclosed herein, using procedures similar to the cited references, are described herein in Examples 1-8 and 12. Based on the cited references and the disclosure herein, one of ordinary skill in the art will be readily able to prepare compounds of the invention.
[0035] In accordance with one aspect of the present invention, compounds corresponding to Formula I may be derived from 2,5-diaminopyrazine-3,6-dicarboxylic acid which, in turn, may be derived from 5-aminouracil. For example, 5-aminouracil may be treated with a ferricyanide in the presence of a base to form, as an intermediate, 2,4,6,8-tetrahydroxypyrimido(4,5-g)pteridine (or a salt thereof), the pteridine intermediate is heated and hydrolyzed using a base, and the hydrolysate is then acidified to yield 2,5-diaminopyrazine-3,6-dicarboxylic as illustrated in Reaction Scheme 1.
##STR00008##
[0036] wherein each Z is independently hydrogen or a monovalent cation. For example, each Z may independently be hydrogen or an alkali metal. In one exemplary embodiment, each Z is hydrogen. In another exemplary embodiment, each Z is an alkali metal. In yet another exemplary embodiment, each Z is lithium, sodium or potassium, but they are different (e.g., one is potassium and the other is lithium or sodium).
[0037] The series of reactions illustrated in Reaction Scheme 1 are generally carried out in a suitable solvent. Typically, the reactions will be carried out in an aqueous system.
[0038] In one embodiment, each equivalent of 5-aminouracil is treated with about 3.0 equivalents of ferricyanide, and the concentration of the base is about 0.5N in the reaction mixture. The ferricyanide used to treat 5-aminouracil may be selected from the group consisting of potassium ferricyanide (K.sub.3Fe(CN).sub.6), lithium ferricyanide (Li.sub.3Fe(CN).sub.6), sodium ferricyanide (Na.sub.3Fe(CN).sub.6), sodium potassium ferricyanide, lithium sodium ferricyanide or lithium potassium ferricyanide. Typically, the ferricyanide will be potassium ferricyanide. The base used in combination with the ferricyanide is preferably an alkali metal hydroxide, e.g., sodium or potassium hydroxide. See, for example, Taylor et al., JACS, 77: 2243-2248 (1955).
[0039] In a preferred embodiment, the hydrolysis mixture is irradiated with microwaves to heat the mixture as the 2,4,6,8-tetrahydroxypyrimido(4,5-g)pteridine (or salt thereof) is hydrolyzed. At least in some embodiments, the microwaves will have a frequency within the range of about 300 MHz to 30 GHz, and the hydrolysis mixture (preferably an aqueous hydrolysis mixture) is heated to a temperature within the range of about 120 to about 180° C. for a period of about 30 to about 90 minutes. For example, in some embodiments, the hydrolysis mixture will be irradiated with microwaves to heat the hydrolysis mixture to a temperature of about 120 to about 140° C. for about 45 to about 75 minutes. In addition to the 2,4,6,8-tetrahydroxypyrimido(4,5-g)pteridine (or salt thereof), the hydrolysis mixture of at least some embodiments will typically contain at least about 4.7 equivalents of a base, preferably an alkali metal hydroxide (e.g., potassium or sodium hydroxide). The resulting hydrolysate may then be acidified, preferably with a mineral acid such as hydrochloric acid, sulfuric acid, or phosphoric acid, more preferably hydrochloric acid, to provide 2,5-diaminopyrazine-3,6-dicarboxylate.
[0040] Methods for the conversion of 2,5-diaminopyrazine-3,6-dicarboxylic acid to other compositions falling within Formula I are known to those of ordinary skill. For example, corresponding 2,5-diaminopyrazine-3,6-diesters and corresponding 2,5-Bis(N,N-dialkylamino) pyrazine-3,6-diesters may be prepared by treating 2,5-diaminopyrazine-3,6-dicarboxylic acid with the appropriate alkylating agent(s), for example, a mono- or dialkyl halide as described in Kim et al., Dyes and Pigments, Vol. 39, pages 341-357 (1998). Alternatively, corresponding 2,5-diaminopyrazine-3,6-dithioesters or corresponding 2,5-Bis(N,N-dialkylamino) pyrazine-3,6-dithioesters may be prepared by treating the 2,5-diaminopyrazine-3,6-dicarboxylic acid with a thiol, or a thiol and the appropriate alkylating agent, respectively, as described in Kim et al., Dyes and Pigments, Vol. 41, pages 183-191 (1999).
[0041] It is noteworthy that the alkylation of the electron donating amino groups in cyano- or carboxypyrazines has a profound effect on electronic transition of the pyrazine chromophore in that the dialkylation of the amino group in 2,5-diamino-3,5-dicyanopyrazine produces large bathochromic shift on the order of about 40-60 nm. It is also noteworthy that the pyrrolidino and piperidino derivatives exhibit substantial differences in their UV spectra (e.g., the former may tend to exhibit a bathochromic shift of about 34 nm).
[0042] One protocol for assessing physiological function of renal cells includes administering an effective amount of a pyrazine derivative that is capable of being renally cleared into a body of a patient. This pyrazine derivative is hydrophilic and capable of absorbing and/or emanating spectral energy of at least about 400 nm. Examples of such pyrazine derivates are those represented by Formulas I and II above. An appropriate dosage of the pyrazine derivative that is administered to the patient is readily determinable by one of ordinary skill in the art and may vary according to such factors as clinical procedure contemplated, solubility, bioavailabilty, and toxicity. By way of example, an appropriate dosage generally ranges from about 1 nanomolar to about 100 micromolar. The administration of the pyrazine derivative to the patient may occur in any of a number of appropriate fashions including, but not limited to: (1) intravenous, intraperitoneal, or subcutaneous injection or infusion; (2) oral administration; (3) transdermal absorption through the skin; and (4) inhalation.
[0043] Still referring to the above-mentioned protocol, the pyrazine derivative in the patient's body is exposed to spectral energy of at least about 400 nm (preferably, visible and/or near infrared light). This exposure of the pyrazine derivative to spectral energy preferably occurs while the pyrazine derivative is in the body (e.g., in the bloodstream). Due to this exposure of the pyrazine derivative to the spectral energy, the pyrazine derivative emanates spectral energy (e.g., visible and/or near infrared light) that may be detected by appropriate detection equipment. The spectral energy emanated from the pyrazine derivative tends to exhibit a wavelength range greater than a wavelength range absorbed by the pyrazine derivative. For example, if a composition of the invention absorbs light of about 700 nm, the composition may emit light of about 745 nm.
[0044] Detection of the pyrazine derivative (or more particularly, the light emanating therefrom) may be achieved through optical fluorescence, absorbance, light scattering or other related procedures known in the art. In some embodiments, this detection of the emanated spectral energy may be characterized as a collection of the emanated spectral energy and a generation of electrical signal indicative of the collected spectral energy. The mechanism(s) utilized to detect the spectral energy from the composition that is present in the body may be designed to detect only selected wavelengths (or wavelength ranges) and/or may include one or more appropriate spectral filters. Various catheters, endoscopes, ear clips, hand bands, head bands, forehead sensors, surface coils, finger probes and the like may be utilized to expose the pyrazine derivatives to light and/or to detect the light emanating therefrom [30]. This detection of spectral energy may be accomplished at one or more times intermittently or may be substantially continuous.
[0045] Renal function of the patient can be determined based on the detected spectral energy. This can be achieved by using data indicative of the detected spectral energy and generating an intensity/time profile indicative of a clearance of the pyrazine derivative from the body. This profile may be correlated to a physiological or pathological condition. For example, the patient's clearance profiles and/or clearance rates may be compared to known clearance profiles and/or rates to assess the patient's renal function and to diagnose the patient's physiological condition. In the case of analyzing the presence of the pyrazine derivative in bodily fluids, concentration/time curves may be generated and analyzed (preferably in real time) using an appropriate microprocessor to diagnose renal function.
[0046] Physiological function can be assessed by any of a number of procedures such as any of the following or similar procedures alone or in any combination: (1) comparing differences in manners in which normal and impaired cells remove a composition of the invention from the bloodstream; (2) measuring a rate or an accumulation of a composition of the invention in the organs or tissues; and (3) obtaining tomographic images of organs or tissues having a composition of the invention associated therewith. For example, blood pool clearance may be measured non-invasively from convenient surface capillaries such as those found in an ear lobe or a finger or can be measured invasively using an appropriate instrument such as an endovascular catheter. Accumulation of a composition of the invention within cells of interest can be assessed in a similar fashion. Incidentally, a “composition” of the invention refers to sterile formulations, aqueous formulations, parenteral formulations and any other formulations including one or more of the pyrazine derivatives of the invention. These compositions of the invention may include pharmaceutically acceptable diluents, carriers, adjuvants, preservatives, excipients, buffers, and the like. The phrase “pharmaceutically acceptable” means those formulations which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
[0047] A modified pulmonary artery catheter may also be utilized to, inter alia, make the desired measurements [32] of spectral energy emanating from a composition of the invention. The ability for a pulmonary catheter to detect spectral energy emanating from a composition of the invention is a distinct improvement over current pulmonary artery catheters that measure only intravascular pressures, cardiac output and other derived measures of blood flow. Traditionally, critically ill patients have been managed using only the above-listed parameters, and their treatment has tended to be dependent upon intermittent blood sampling and testing for assessment of renal function. These traditional parameters provide for discontinuous data and are frequently misleading in many patient populations.
[0048] Modification of a standard pulmonary artery catheter only requires making a fiber optic sensor thereof wavelength-specific. Catheters that incorporate fiber optic technology for measuring mixed venous oxygen saturation exist currently. In one characterization, it may be said that the modified pulmonary artery catheter incorporates a wavelength-specific optical sensor into a tip of a standard pulmonary artery catheter. This wavelength-specific optical sensor can be utilized to monitor renal function specific elimination of a designed optically detectable chemical-entity such as the compositions of the present invention. Thus, by a method analogous to a dye dilution curve, real-time renal function can be monitored by the disappearance/clearance of an optically detected compound.
[0049] The following examples illustrate specific embodiments of this invention. As would be apparent to skilled artisans, various changes and modifications are possible and are contemplated within the scope of the invention described.
Example 1
Prophetic
Preparation of 36-dicyano-2,5-[(N,N,N′,N′-tetrakis(carboxymethyl)amino]pyrazine
[0050] ##STR00009##
[0051] Step 1.
[0052] A stirring mixture of 2,5-diamino-3,6-dicyanopyrazine (10 mmol) and t-butyl bromoacetate (42 mmol) in distilled dimethylacetamide (25 mL) is cooled in ice and subsequently treated with powdered sodium hydroxide (50 mmol). After stirring at ambient temperature for about 2 hours, the reaction mixture is treated water (200 mL) and methylene chloride (100 mL). An organic layer of the mixture is washed with copious water, next dried over sodium sulfate, then filtered, and subsequently the filtrate evaporated in vacuo. The crude product is then purified by flash chromatography to give tetra-t-butyl ester.
[0053] Step 2.
[0054] The tetraester from Step 1 (10 mmol) is treated with 96% formic acid (10 mL) and heated to boiling for about 1 minute and kept at about 40-50° C. for approximately 16 hours. The reaction mixture is poured onto ether causing formation of a precipitate. This resulting precipitate is separated from the ether layer by decantation, and then purified by chromatography or recrystallization.
Example 2
Prophetic
Preparation of 3,6-(N,N,N′,N′-tetrakis(2-hydroxyethyl)aminopyrazine-2,5-dicarboxylic acid
[0055] ##STR00010##
[0056] Step 1.
[0057] The alkylation procedure is identical to the one in Step 1 of Example 1, except that 2-iodoethanol is used instead of t-butylbromoacetate.
[0058] Step 2.
[0059] The dicyano compound from Step 1 (10 mmol) is dissolved in concentrated sulfuric acid (10 mL) and stirred at ambient temperature for about 3 hours. The reaction mixture is carefully diluted with water (100 mL), and the product is collected by filtration and subsequently dried to give the corresponding carboxamide intermediate.
[0060] Step 3.
[0061] The biscarboxamide derivative from Step 2 (10 mmol) is dissolved in potassium hydroxide solution (25 mmol in 25 mL of water) and heated under reflux for about 3 hours. After cooling, the solution is acidified with 1N HCl (25 mL). The product is collected by filtration, dried, and purified by recyrstallization or chromatography.
Preparation of 3,5-[(N,N,N′,N′-tetrakis(2-hydroxyethyl)amino]-pyrazine-2,6-dicarboxylic acid (compound of Formula II) can be accomplished in a similar manner using 2,6-diamino-3,5-dicyanopyazine as the starting material
[0062] Alternatively, 3,6-[(N,N,N′,N′-tetrakis(2-hydroxyethyl)amino]pyrazine-2,5-dicarboxylic acid may be prepared by N-alkylating 3,6-diaminopyrazine-2,5-dicarboxylic acid (Example 16) with 2-iodoethanol as described in Step 1.
Example 3
Prophetic
Preparation of 3,6-bis(N-azetadino)pyrazine-2,5-dicarboxylic acid
[0063] ##STR00011##
[0064] Step 1.
[0065] The alkylation procedure is substantially identical to the one in Step 1 of Example 1, except that 1,3-dibromopropane is used instead of t-butylbromoacetate.
[0066] Step 2.
[0067] The hydrolysis procedure is substantially identical to the one in Step 2 of Example 2, except that the starting material is 3,6-dicyano-2,5-bis(N-azetadino)pyrazine.
[0068] Step 3.
[0069] The hydrolysis procedure is substantially identical to the one in Step 3 of Example 2, except that the starting material is 3,6-bis(N-azetadino)-2,5-pyrazinedicarboxamide.
[0070] Preparation of 3,5-bis(N-azetadino)pyrazine-2,6-dicarboxylic acid (compound of Formula II) can be accomplished in a similar fashion using 2,6-diamino-3,5-dicyanopyazine as the starting material.
[0071] Alternatively, 3,6-bis(N-azetadino)pyrazine-2,5-dicarboxylic acid may be prepared by N-alkylating 3,6-diaminopyrazine-2,5-dicarboxylic acid (Example 16) with 1,3-dibromopropane as described in Step 1.
Example 4
Prophetic
Preparation of 3,6-bis(N-morpholino)pyrazine-2,5-dicarboxylic acid
[0072] ##STR00012##
[0073] Step 1.
[0074] The alkylation procedure is identical to the one in Step 1, Example 1 except that bis(2-chloroethyl) ether is used instead of t-butylbromoacetate.
[0075] Step 2.
[0076] The hydrolysis procedure is identical to the one in Step 2, Example 2 except that the starting material is 3,6-dicyano-2,5-bis(N-morpholino)pyrazine.
[0077] Step 3.
[0078] The hydrolysis procedure is identical to the one in Step 3, Example 2 except that the starting material is 3,6-bis(N-morpholino)-2,5-pyrazinedicarboxamide.
[0079] Preparation of 3,5-bis(N-morpholino)pyrazine-2,6-dicarboxylic acid (compound belonging to Formula II) can be accomplished in the same manner using 2,6-diamino-3,5-dicyanopyazine as the starting material.
[0080] Alternatively, 3,6-bis(N-morpholino)pyrazine-2,5-dicarboxylic acid may be prepared by N-alkylating 3,6-diaminopyrazine-2,5-dicarboxylic acid (Example 16) with (2-chloroethyl) ether as described in Step 1.
Example 5
Prophetic
Preparation of 3,6-bis(N-piperazino)pyrazine-2,5-dicarboxylic acid
[0081] ##STR00013##
[0082] Step 1.
[0083] The alkylation procedure is identical to the one in Step 1, Example 1 except that bis(2-chloroethyl) amine is used instead of t-butylbromoacetate.
[0084] Step 2.
[0085] The hydrolysis procedure is identical to the one in Step 2, Example 2 except that the starting material is 3,6-dicyano-2,5-bis(N-piperazino)pyrazine.
[0086] Step 3.
[0087] The hydrolysis procedure is identical to the one in Step 3, Example 2 except that the starting material is 3,6-bis(N-piperazino)-2,5-pyrazinedicarboxamide.
[0088] Preparation of 3,5-bis(N-piperazino)pyrazine-2,6-dicarboxylic acid (compound belonging to Formula II) can be accomplished in the same manner using 2,6-diamino-3,5-dicyanopyazine as the starting material.
[0089] Alternatively, 3,6-bis(N-piperazino)pyrazine-2,5-dicarboxylic acid may be prepared by N-alkylating 3,6-diaminopyrazine-2,5-dicarboxylic acid (Example 16) with bis(2-chloroethyl) amine as described in Step 1.
Example 6
Prophetic
Preparation of 3,6-bis(N-thiomorpholino)pyrazine-2,5-dicarboxylic acid
[0090] ##STR00014##
[0091] Step 1.
[0092] A mixture of the tetralcohol product from Step 1, Example 2, (10 mmol), and triethylamine (44 mmol) in anhydrous tetrahydrofuran (50 mL) cooled to 0° C. and treated with methanesulfonyl chloride (42 mmol) added in portion in such a manner that the temperature is maintained at 0 to 15° C. After the addition, the reaction mixture is stirred at ambient temperature for 16 hours. The reaction mixture is then filtered and the filtrate taken to dryness under reduced pressure.
[0093] The residue is then redissolved in methanol (20 mL) and treated with sodium sulfide (22 mmol). The reaction mixture is then heated under reflux for 16 hours and poured onto water (100 mL) and extracted with ethyl acetate. The combined organic layer is washed with copious water, dried over sodium sulfate, filtered, and the filtrate evaporated in vacuo. The crude product is then purified by flash chromatography to give the bis(thiomorpholino)pyrazine diester.
[0094] Step 2.
[0095] The hydrolysis procedure is identical to the one in Step 2, Example 2 except that the starting material is 3,6-dicyano-2,5-bis(N-thiomorpholino)pyrazine.
[0096] Step 3.
[0097] The hydrolysis procedure is identical to the one in Step 3, Example 2 except that the starting material is 3,6-bis(N-thiomorpholino)-2,5-pyrazinedicarboxamide.
[0098] Preparation of 3,5-bis(N-thiomorpholino)pyrazine-2,6-dicarboxylic acid (compound belonging to Formula II) can be accomplished in the same manner using 2,6-diamino-3,5-dicyanopyazine as the starting material.
Example 7
Prophetic
Preparation of 3,6-bis(N-thiomorpholino)pyrazine-2,5-dicarboxylic acid S-oxide
[0099] ##STR00015##
[0100] Step 1.
[0101] The bis(thiomorpholino)pyrazine derivative from Step 3, Example 6 (5 mmol) is dissolved in methanol (20 mL) and treated with m-chloroperoxybenzoic acid (11 mmol) and heated under reflux for 16 hours. The reaction mixture poured onto saturated sodium bicarbonate (20 mL) and extracted with methylene chloride. The combined organic layer is washed with brine, dried over sodium sulfate, filtered, and the filtrate evaporated in vacuo. The crude product is purified by chromatography or recrystallization.
[0102] Step 2.
[0103] The procedure is identical to Step 2, Example 6 except that thiomorpholino-S-oxide is used in this experiment.
[0104] Preparation of 3,5-bis(N-thiomorpholino)pyrazine-2,6-dicarboxylic acid S-oxide (compound belonging to Formula II) can be accomplished in the same manner using 2,6-diamino-3,5-dicyanopyazine as the starting material, followed by hydrolysis of the nitrile as outlined in Example 1, Step 2 or Example 2, Steps 2 and 3.
Example 8
Prophetic
Preparation of 2,5-dicyano-3,6-bis(N-thiomorpholino)pyrazine S,S-dioxide
[0105] ##STR00016##
[0106] Step 1.
[0107] The procedure is identical to Step 1, Example 7 except that thiomorpholino-S-oxide is used in this experiment.
[0108] Step 2.
[0109] The procedure is identical to Step 2, Example 6 except that thiomorpholino-S,S-dioxide is used in this experiment.
Example 9
Prophetic
[0110] Protocol for Assessing Renal Function.
[0111] An example of an in vivo renal monitoring assembly 10 is shown in
[0112] Still referring to
[0113] In one protocol for determining renal function, an effective amount of a composition including a pyrazine derivative of the invention is administered to the patient. At least a portion of the body of the patient 20 is exposed to visible and/or near infrared light from the light source 12 as indicated by arrow 16. For instance, the light from the light source 12 may be delivered via a fiber optic that is affixed to an ear of the patient 20. The patient may be exposed to the light from the light source 12 before or after administration of the composition to the patient 20. In some cases, it may be beneficial to generate a background or baseline reading of light being emitted from the body of the patient 20 (due to exposure to the light from the light source 12) before administering the composition to the patient 20. When the pyrazine derivative(s) of the composition that are in the body of the patient 20 are exposed to the light from the light source 12, the pyrazine derivative(s) emanate light (indicated by arrow 18) that is detected/collected by the data processing system 14. Initially, administration of the composition to the patient 20 generally enables an initial spectral signal indicative of the initial content of the pyrazine derivative(s) in the patient 20. The spectral signal then tends to decay as a function of time as the pyrazine derivative(s) is cleared from the patient 20. This decay in the spectral signal as a function of time is indicative of the patient's renal function. For example, in a first patient exhibiting healthy/normal renal function, the spectral signal may decay back to a baseline in a time of T. However, a spectral signal indicative of a second patient exhibiting deficient renal function may decay back to a baseline in a time of T+4 hours. As such, the patient 20 may be exposed to the light from the light source 12 for any amount of time appropriate for providing the desired renal function data. Likewise, the data processing system 14 may be allowed to collect/detect spectral energy for any amount of time appropriate for providing the desired renal function data.
Example 10
Actual
Assessment of Renal Function of Normal Rat
[0114] Incident laser light having a wavelength of about 470 nm was delivered from a fiber optic bundle to the ear of an anesthetized Sprague-Dawley rat. While the light was being directed at the ear, data was being acquired using a photodector to detect fluorescence coming from within the ear. A background reading of fluorescence was obtained prior to administration of the pyrazine agent. Next, the pyrazine agent (in this case, 2 ml of a 0.4 mg/ml solution of 3,6-diaminopyrazine-2,5-dicarboxylic acid in PBS) (Example 16) was administered into the rat through a bolus injection in the lateral tail vein. As shown in
##STR00017##
[0115] The blood clearance time profiles reported herein were assumed to follow a two compartment pharmacokinetic model. The fluorescent signal (arising from the dye concentration in the blood) as a function of time was therefore fit to a double exponential decay. The equation employed to fit the data was:
S=Ae.sup.−t/τ.sub.1+Be.sup.−t/τ.sub.2+C (1)
where S is the fluorescent light intensity signal measured, t is the time point of the measurement, and e refers to the mathematical constant having a numerical value of about 2.71828182846. The decay times τ.sub.1 and τ.sub.2, and the constants A, B, and C are deduced from the fitting procedure. The non-linear regression analysis package within SigmaPlot® (Systat Software Inc., Richmond, Calif.) was employed to fit data to Eq. (1). In Examples 10 and 11, τ.sub.1 represents the time constant for vascular-extracellular fluid equilibrium, and τ.sub.2 represents the dye clearance from the blood.
Example 11
Actual
Assessment of Renal Function of Bilaterally Nephrectomized Rat
[0116] An anesthetized Sprague-Dawley rat was bilaterally nephrectomized. Incident laser light having a wavelength of about 470 nm was delivered from a fiber optic bundle to the ear of rat. While the light was being directed at the ear, data was being acquired using a photodector to detect fluorescence coming from within the ear. A background reading of fluorescence was obtained prior to administration of the pyrazine agent. Next, the pyrazine agent (again, in this case, 2 ml of a 0.4 mg/ml solution of 3,6-diaminopyrazine-2,5-dicarboxylic acid in PBS) was administered into the rat through a bolus injection in the lateral tail vein. As shown in
Example 12
Actual
Preparation of 3,6-dicyano-25-[(N,N,N′,N′-tetrakis(carboxymethyl)amino]pyrazine
[0117] ##STR00018##
[0118] Step 1.
[0119] A stirring mixture of 2,5-diamino-3,6-dicyanopyrazine (1 mmol) and t-butyl bromoacetate (16 mmol) in dimethylacetamide (5 mL) was cooled in an ice-water-bath and subsequently treated with powdered NaOH (6 mmol). The contents were allowed to warm to ambient temperature over 1 h, then the reaction mixture was treated with deionized water (50 mL). This aqueous mixture was extracted twice with methylene chloride (50 mL). The combined organic extracts were dried over sodium sulfate, filtered, and concentrated in vacuo to afford an oil. This oil was purified by flash chromatography to give the tetra-t-butyl ester.
[0120] Step 2.
[0121] The tetraester from Step 1 (0.86 mmol) was heated in glacial acetic acid (50 mL) for 24 hours, then was allowed to cool to ambient temperature. The solution was filtered and concentrated in vacuo to afford an oil. The oil was purified by preparative HPLC to afford the title compound.
Example 13
Prophetic
Preparation of 2,6-dicyano-3,5-[(N,N,N′,N′-tetrakis(hydroxyethyl)amino]pyrazine
[0122] ##STR00019##
[0123] To a stirring solution of mixture of tetracyanopyrazine (10 mmol) in tetrahydrofuran (25 mL) is treated with dropwise addition of diethanolamine (50 mmol) over 30 minutes. After the addition, the mixture is stirred at ambient temperature for additional 1 hour. The crude product is collected by filtration and purified by chromatography or recrystallization.
Example 14
Prophetic
Preparation of 2,6-dicyano-3.5-[(N,N′-bis(hydroxyethyl)amino]pyrazine
[0124] ##STR00020##
[0125] The procedure is identical to Example 13 except that aminopropanediol is used in instead of diethanolamine.
Example 15
Prophetic
Preparation of 2,6-dicyano-3,5-[(N,N′-bis(prolyl)amino]pyrazine
[0126] ##STR00021##
[0127] The procedure is identical to Example 13 except that proline is used in instead of diethanolamine.
Example 16
Actual
Synthesis of 3,6-diaminopyrazine-2,5-dicarboxylic acid
[0128] ##STR00022##
[0129] Dipotassium 2,4,6,8-tetrahydroxypyrimido(4,5-g)pteridine was prepared by treating 5-aminouracil with potassium ferricyanide in the presence of potassium hydroxide as described in Taylor et al., JACS, 77: 2243-2248 (1955).
[0130] In each of two Teflon reaction vessels was placed 0.5 g dipotassium 2,4,6,8-tetrahydroxypyrimido[4,5g]pteridine and a solution consisting of 0.3-0.4 g sodium hydroxide in about 10 mL deionized water. The vessels were secured in the microwave reactor and allowed to react for one hour at 170° C., generating ca. 100 psi pressure, for one hour. The vessels were allowed to cool in the microwave to ca. 50° C. and the contents filtered to remove a small amount of solid residue. The bright yellow filtrate was transferred to a 250 mL round-bottom flask equipped with a large magnetic stir bar.
[0131] With stirring, the pH was adjusted to ca. 3 with concentrated HCl. A large amount of red precipitate formed. A few more drops of acid was added and the solid collected by filtration on a glass frit, washed with cold 1×10 mL 1N HCl, 2×30 mL acetonitrile and 1×30 mL diethyl ether, suctioned dry and transferred to a vacuum oven, vacuum drying overnight at 45-50° C. Yield 0.48 g (79%). C13 NMR (D.sub.2O/NaOD, external TMS reference) δ 132.35, 147.32, 171.68.
[0132] An aliquot of the bright yellow solution was concentrated in vacuo resulting in the formation of two sets of crystals: red needles and yellow blocks. X-Ray crystallography revealed that both crystals are disodium 2,5-diamino-3,6-(dicarboxylato)pyrazine. The crystal data and structure refinement for the two sets of crystals are set forth in Tables 1R-6R (red crystals) and Tables 1Y-6Y (yellow blocks). Their structures are shown in
Example 17
Prophetic
Preparation of 2,5-dicyano 3,6-[(N,N′-bis(2,3-dihydroxyhydroxypropyl)amino]-pyrazine
[0133] ##STR00023##
[0134] The alkylation procedure is identical to the one in Step 1 of Example 1, except that 3-bromo-1,2-propanediol is used instead of t-butylbromoacetate.
Example 18
Prophetic
Preparation of 3,6-[(N,N′-bis(23-dihydroxypropyl)amino]pyrazine-2,5-dicarboxylic acid
[0135] ##STR00024##
[0136] Step 1.
[0137] The alkylation procedure is identical to the one in Step 1 of Example 1, except that 3-bromo-1,2-propanediol is used instead of t-butylbromoacetate.
[0138] Step 2.
[0139] The hydrolysis procedure is identical to the one in Step 2 of Example 2, except that the starting material is the cyano compound in Example 17.
[0140] Step 3.
[0141] The hydrolysis procedure is identical to the one in Step 3.
Example 19
Prophetic
Preparation of 2,5-dicyano 3,6-[(N,N′-bis(23-dihydroxyhydroxypropyl)amino]-N,N′-dimethylaminopyrazine
[0142] ##STR00025##
[0143] The cyano compound (10 mmol) from Example 17 is dissolved in dimethylformamide (10 mL) and treated with dimethylsulfate (30 mmol). The mixture is heated at 100° C. for 4 hours and triturated with acetone (100 mL). The crude product is then collected and purified by either crystallization or chromatography.
Example 20
Prophetic
Preparation of 3,6-[(N,N-bis(dimethylamino]pyrazine-2,5-dicarboxylic acid
[0144] ##STR00026##
[0145] The title compound is prepared by the hydrolysis of the corresponding dicyano compound by the procedure described in Steps 2 and 3 of Example 2.
Example 21
Prophetic
Preparation of 2,5-dicyano 3,6-[(N,N′-bis(2-sulfonatoethyl)amino]-pyrazine
[0146] ##STR00027##
[0147] The alkylation procedure is identical to the one in Step 1 of Example 1, except that taurine (2-aminoethanesulfonate) is used instead of t-butylbromoacetate.
Example 22
Prophetic
Preparation of 2,5-bis[(N,N′-(2-sulfonato)ethyl]carbamoyl-3,6-[(N,N-bis-(dimethylamino)]pyrazine
[0148] ##STR00028##
[0149] A mixture of the diacid in Example 20 (10 mmol), taurine (22 mmol) and the water-soluble carbodiimide, EDC (ethyldimethylaminopropylcarbodiimide) (25 mmol) in water/DMF (1:1) is stirred at ambient temperature for 16 hours. The solvent is evaporated in vacuo and the crude product is purified by chromatography.
TABLE-US-00001 TABLE 1Y Crystal data and structure refinement for dm16005 (yellow). Identification code m16005/lt/B3401P021-yellow Empirical formula C3H8N2NaO5 Formula weight 175.10 Temperature 100(2) K Wavelength 0.71073 Å Crystal system Monoclinic Space group P2.sub.1/c Unit cell dimensions a = 10.5000(10) Å α = 90°. b = 5.2583(5) Å β = 103.207(4)°. c = 13.0181(11) Å γ = 90°. Volume 699.75(11) Å.sup.3 Z 4 Density (calculated) 1.662 Mg/m.sup.3 Absorption coefficient 0.204 mm.sup.−1 F (000) 364 Crystal size 0.23 × 0.19 × 0.13 mm.sup.3 Theta range for data collection 1.99 to 39.00°. Index ranges −18 ≦ h ≦ 17, −9 ≦ k ≦ 9, −22 ≦ l ≦ 23 Reflections collected 17310 Independent reflections 4040 [R(int) = 0.04] Completeness to theta = 39.00° 99.4% Absorption correction Semi-empirical from equivalents Max. and min. transmission 0.9739 and 0.9545 Refinement method Full-matrix least-squares on F.sup.2 Data/restraints/parameters 4040/0/132 Goodness-of-fit on F.sup.2 1.045 Final R indices [I > 2sigma(I)] R1 = 0.0365, wR2 = 0.0924 R indices (all data) R1 = 0.0514, wR2 = 0.1005 Largest diff. peak and hole 0.744 and −0.309 e .Math. Å.sup.−3
TABLE-US-00002 TABLE 2Y Atomic coordinates (×10.sup.4) and equivalent isotropic displacement parameters (Å.sup.2 × 10.sup.3) for dm16005. U(eq) is defined as one third of the trace of the orthogonalized U.sup.ij tensor. x y z U(eq) Na(1) 5013(1) 585(1) 3712(1) 10(1) O(1) 6904(1) 3242(1) 4474(1) 11(1) O(2) 8116(1) 5088(1) 3474(1) 13(1) O(3) 6108(1) −1620(1) 2599(1) 11(1) O(4) 3129(1) −2477(1) 3412(1) 14(1) O(5) 3823(1) 2092(1) 4915(1) 11(1) N(1) 8824(1) −4(1) 5294(1) 10(1) N(2) 9494(1) −3201(2) 6512(1) 18(1) C(1) 7933(1) 3462(1) 4135(1) 9(1) C(2) 9036(1) 1636(1) 4569(1) 9(1) C(3) 9759(1) −1648(1) 5744(1) 10(1)
TABLE-US-00003 TABLE 3Y Bond lengths [Å] and angles [°] for dm16005. Na(1)—O(3) 2.3511(6) Na(1)—O(5) 2.3532(6) Na(1)—O(3)#1 2.3533(7) Na(1)—O(5)#2 2.3815(7) Na(1)—O(1) 2.4457(6) Na(1)—O(4) 2.5110(7) Na(1)—Na(1)#2 3.4155(7) Na(1)—Na(1)#3 4.1027(5) Na(1)—Na(1)#1 4.1027(5) O(1)—C(1) 1.2618(8) O(2)—C(1) 1.2592(9) O(3)—Na(1)#3 2.3534(7) O(3)—H(3A) 0.869(15) O(3)—H(3B) 0.823(15) O(4)—H(4A) 0.878(17) O(4)—H(4B) 0.827(17) O(5)—Na(1)#2 2.3814(7) O(5)—H(5A) 0.874(16) O(5)—H(5B) 0.871(14) N(1)—C(2) 1.3339(9) N(1)—C(3) 1.3385(9) N(2)—C(3) 1.3687(10) N(2)—H(2A) 0.862(14) N(2)—H(2B) 0.891(14) C(1)—C(2) 1.5105(10) C(2)—C(3)#4 1.4153(10) C(3)—C(2)#4 1.4152(10) O(3)—Na(1)—O(5) 170.15(2) O(3)—Na(1)—O(3)#1 95.449(17) O(5)—Na(1)—O(3)#1 91.07(2) O(3)—Na(1)—O(5)#2 86.08(2) O(5)—Na(1)—O(5)#2 87.66(2) O(3)#1—Na(1)—O(5)#2 177.57(2) O(3)—Na(1)—O(1) 93.75(2) O(5)—Na(1)—O(1) 92.47(2) O(3)#1—Na(1)—O(1) 99.33(2) O(5)#2—Na(1)—O(1) 78.66(2) O(3)—Na(1)—O(4) 93.84(2) O(5)—Na(1)—O(4) 78.47(2) O(3)#1—Na(1)—O(4) 92.42(2) O(5)#2—Na(1)—O(4) 89.36(2) O(1)—Na(1)—O(4) 165.33(2) O(3)—Na(1)—Na(1)#2 129.13(2) O(5)—Na(1)—Na(1)#2 44.160(16) O(3)#1—Na(1)—Na(1)#2 135.20(2) O(5)#2—Na(1)—Na(1)#2 43.502(15) O(1)—Na(1)—Na(1)#2 83.835(18) O(4)—Na(1)—Na(1)#2 81.636(18) O(3)—Na(1)—Na(1)#3 29.317(15) O(5)—Na(1)—Na(1)#3 144.77(2) O(3)#1—Na(1)—Na(1)#3 85.888(19) O(5)#2—Na(1)—Na(1)#3 96.338(17) O(1)—Na(1)—Na(1)#3 122.678(18) O(4)—Na(1)—Na(1)#3 66.623(15) Na(1)#2—Na(1)—Na(1)#3 129.770(12) O(3)—Na(1)—Na(1)#1 76.118(19) O(5)—Na(1)—Na(1)#1 112.639(17) O(3)#1—Na(1)—Na(1)#1 29.285(14) O(5)#2—Na(1)—Na(1)#1 150.22(2) O(1)—Na(1)—Na(1)#1 78.905(15) O(4)—Na(1)—Na(1)#1 115.15(2) Na(1)#2—Na(1)—Na(1)#1 150.502(13) Na(1)#3—Na(1)—Na(1)#1 79.709(13) C(1)—O(1)—Na(1) 126.28(5) Na(1)—O(3)—Na(1)#3 121.40(3) Na(1)—O(3)—H(3A) 116.0(10) Na(1)#3—O(3)—H(3A) 102.3(10) Na(1)—O(3)—H(3B) 105.9(10) Na(1)#3—O(3)—H(3B) 105.7(10) H(3A)—O(3)—H(3B) 103.9(13) Na(1)—O(4)—H(4A) 98.7(11) Na(1)—O(4)—H(4B) 102.9(11) H(4A)—O(4)—H(4B) 109.9(14) Na(1)—O(5)—Na(1)#2 92.34(2) Na(1)—O(5)—H(5A) 114.6(11) Na(1)#2—O(5)—H(5A) 97.3(10) Na(1)—O(5)—H(5B) 131.9(9) Na(1)#2—O(5)—H(5B) 111.0(9) H(5A)—O(5)—H(5B) 103.8(13) C(2)—N(1)—C(3) 120.18(6) C(3)—N(2)—H(2A) 119.5(9) C(3)—N(2)—H(2B) 117.4(9) H(2A)—N(2)—H(2B) 115.5(12) O(2)—C(1)—O(1) 125.27(7) O(2)—C(1)—C(2) 117.65(6) O(1)—C(1)—C(2) 117.08(6) N(1)—C(2)—C(3)#4 120.73(6) N(1)—C(2)—C(1) 116.00(6) C(3)#4—C(2)—C(1) 123.27(6) N(1)—C(3)—N(2) 116.98(6) N(1)—C(3)—C(2)#4 119.09(6) N(2)—C(3)—C(2)#4 123.90(7) Symmetry transformations used to generate equivalent atoms: #1−x + 1, y + 1/2, −z + 1/2 #2−x + 1, −y, −z + 1 #3−x + 1, y − 1/2, −z + 1/2 #4−x + 2, −y, −z + 1
TABLE-US-00004 TABLE 4Y Anisotropic displacement parameters (Å.sup.2 × 10.sup.3) for dm16005. The anisotropic displacement factor exponent takes the form: −2π.sup.2[h.sup.2 a*.sup.2U.sup.11 + . . . + 2 h k a* b* U.sup.12] U.sup.11 U.sup.22 U.sup.33 U.sup.23 U.sup.13 U.sup.12 Na(1) 10(1) 11(1) 11(1) 0(1) 3(1) 1(1) O(1) 8(1) 10(1) 14(1) 0(1) 4(1) 1(1) O(2) 12(1) 13(1) 15(1) 5(1) 4(1) 3(1) O(3) 12(1) 11(1) 11(1) 1(1) 3(1) 2(1) O(4) 17(1) 14(1) 12(1) 0(1) 5(1) 2(1) O(5) 11(1) 10(1) 14(1) −1(1) 5(1) 1(1) N(1) 8(1) 10(1) 12(1) 2(1) 3(1) 2(1) N(2) 12(1) 20(1) 23(1) 13(1) 9(1) 6(1) C(1) 8(1) 9(1) 10(1) −1(1) 1(1) 1(1) C(2) 8(1) 9(1) 10(1) 1(1) 2(1) 1(1) C(3) 9(1) 11(1) 12(1) 2(1) 4(1) 1(1)
TABLE-US-00005 TABLE 5Y Hydrogen coordinates (×10.sup.4) and isotropic displacement parameters (Å.sup.2 × 10.sup.3) for dm16005. x y z U(eq) H(3A) 6776(14) −2530(30) 2911(12) 29(4) H(3B) 6428(13) −520(30) 2284(11) 29(3) H(4A) 2538(16) −1520(30) 3001(14) 40(4) H(4B) 2966(15) −2590(30) 4003(14) 34(4) H(5A) 3053(15) 1390(30) 4852(13) 36(4) H(5B) 3726(12) 3610(30) 5152(11) 25(3) H(2A) 9998(13) −4480(30) 6728(11) 22(3) H(2B) 8657(14) −3410(30) 6531(11) 30(3)
TABLE-US-00006 TABLE 6Y Torsion angles [°] for dm16005. O(3)—Na(1)—O(1)—C(1) 11.94(6) O(5)—Na(1)—O(1)—C(1) −175.71(6) O(3)#1—Na(1)—O(1)—C(1) −84.22(6) O(5)#2—Na(1)—O(1)—C(1) 97.17(6) O(4)—Na(1)—O(1)—C(1) 132.96(9) Na(1)#2—Na(1)—O(1)—C(1) 140.92(6) Na(1)#3—Na(1)—O(1)—C(1) 6.88(6) Na(1)#1—Na(1)—O(1)—C(1) −63.12(6) O(5)—Na(1)—O(3)—Na(1)#3 59.71(15) O(3)#1—Na(1)—O(3)—Na(1)#3 −71.52(4) O(5)#2—Na(1)—O(3)—Na(1)#3 110.37(3) O(1)—Na(1)—O(3)—Na(1)#3 −171.28(3) O(4)—Na(1)—O(3)—Na(1)#3 21.28(3) Na(1)#2—Na(1)—O(3)—Na(1)#3 103.62(3) Na(1)#1—Na(1)—O(3)—Na(1)#3 −93.69(3) O(3)—Na(1)—O(5)—Na(1)#2 50.56(15) O(3)#1—Na(1)—O(5)—Na(1)#2 −177.93(2) O(5)#2—Na(1)—O(5)—Na(1)#2 0.0 O(1)—Na(1)—O(5)—Na(1)#2 −78.54(2) O(4)—Na(1)—O(5)—Na(1)#2 89.82(2) Na(1)#3—Na(1)—O(5)—Na(1)#2 97.68(3) Na(1)#1—Na(1)—O(5)—Na(1)#2 −157.54(2) Na(1)—O(1)—C(1)—O(2) 90.49(8) Na(1)—O(1)—C(1)—C(2) −90.07(7) C(3)—N(1)—C(2)—C(3)#4 0.69(12) C(3)—N(1)—C(2)—C(1) −178.18(6) O(2)—C(1)—C(2)—N(1) 177.82(6) O(1)—C(1)—C(2)—N(1) −1.66(9) O(2)—C(1)—C(2)—C(3)#4 −1.02(10) O(1)—C(1)—C(2)—C(3)#4 179.50(7) C(2)—N(1)—C(3)—N(2) 177.38(7) C(2)—N(1)—C(3)—C(2)#4 −0.67(12) Symmetry transformations used to generate equivalent atoms: #1−x + 1, y + 1/2, −z + 1/2 #2−x + 1, −y, −z + 1 #3−x + 1, y − 1/2, −z + 1/2 #4−x + 2, −y, −z + 1
TABLE-US-00007 TABLE 1R Crystal data and structure refinement for dm16105. Identification code m16105/lt/B3401P021-red Empirical formula C.sub.6H.sub.8N.sub.4Na2O.sub.6 Formula weight 278.14 Temperature 100(2) K Wavelength 0.71073 Å Crystal system Monoclinic Space group C2/c Unit cell dimensions a = 20.549(6) Å α = 90°. b = 3.5198(9) Å β = 100.56(2)°. c = 13.289(4) Å γ = 90°. Volume 944.9(5) Å.sup.3 Z 4 Density (calculated) 1.955 Mg/m.sup.3 Absorption coefficient 0.245 mm.sup.−1 F (000) 568 Crystal size 0.15 × 0.08 × 0.03 mm.sup.3 Theta range for data collection 2.02 to 23.29°. Index ranges −22 ≦ h ≦ 22, −3 ≦ k ≦ 3, −14 ≦ l ≦ 14 Reflections collected 5401 Independent reflections 673 [R(int) = 0.11] Completeness to theta = 23.29° 99.9% Absorption correction None Max. and min. transmission 0.9927 and 0.9641 Refinement method Full-matrix least-squares on F.sup.2 Data/restraints/parameters 673/1/94 Goodness-of-fit on F.sup.2 1.128 Final R indices [I > 2sigma(I)] R1 = 0.0656, wR2 = 0.1678 R indices (all data) R1 = 0.1011, wR2 = 0.1953 Largest diff. peak and hole 0.553 and −0.459 e .Math. Å.sup.−3
TABLE-US-00008 TABLE 2R Atomic coordinates (×10.sup.4) and equivalent isotropic displacement parameters (Å.sup.2 × 10.sup.3) for dm16105. U(eq) is defined as one third of the trace of the orthogonalized U.sup.ij tensor. x y z U(eq) Na(1) 0 4107(10) −2500 18(1) Na(2) 2500 2500 0 18(1) O(1) 1044(2) 5915(13) −1625(3) 18(1) O(2) 1697(2) 7546(12) −166(3) 17(1) O(3) 2678(2) 1457(16) 1788(3) 23(1) N(1) −24(2) 8853(15) −999(3) 14(1) N(2) −1135(3) 10283(16) −1427(4) 17(1) C(1) 1146(3) 7295(18) −736(5) 14(2) C(2) 548(3) 8715(18) −334(4) 14(1) C(3) −579(3) 10076(18) −695(4) 14(1)
TABLE-US-00009 TABLE 3R Bond lengths [Å] and angles [°] for dm16105. Na(1)—O(1) 2.334(4) Na(1)—O(1)#1 2.334(4) Na(1)—N(1) 2.609(5) Na(1)—N(1)#1 2.609(5) Na(1)—N(1)#2 2.727(5) Na(1)—N(1)#3 2.727(5) Na(1)—Na(1)#3 3.5198(9) Na(1)—Na(1)#4 3.5198(9) Na(2)—O(3)#5 2.365(5) Na(2)—O(3) 2.365(5) Na(2)—O(2)#6 2.383(4) Na(2)—O(2)#3 2.383(4) Na(2)—O(2)#5 2.407(4) Na(2)—O(2) 2.407(4) Na(2)—Na(2)#3 3.5198(9) Na(2)—Na(2)#4 3.5198(9) Na(2)—H(3A) 2.63(7) O(1)—C(1) 1.259(7) O(2)—C(1) 1.244(7) O(2)—Na(2)#4 2.383(4) O(3)—H(3A) 0.96(8) O(3)—H(3B) 0.84(11) N(1)—C(2) 1.335(8) N(1)—C(3) 1.350(8) N(1)—Na(1)#4 2.727(5) N(2)—C(3) 1.359(7) N(2)—H(2A) 0.87(4) N(2)—H(2B) 0.87(4) C(1)—C(2) 1.512(9) C(2)—C(3)#7 1.422(9) C(3)—C(2)#7 1.422(9) O(1)—Na(1)—O(1)#1 148.4(3) O(1)—Na(1)—N(1) 65.72(16) O(1)#1—Na(1)—N(1) 93.56(17) O(1)—Na(1)—N(1)#1 93.56(17) O(1)#1—Na(1)—N(1)#1 65.72(16) N(1)—Na(1)—N(1)#1 100.4(2) O(1)—Na(1)—N(1)#2 114.29(16) O(1)#1—Na(1)—N(1)#2 87.62(15) N(1)—Na(1)—N(1)#2 177.1(2) N(1)#1—Na(1)—N(1)#2 82.51(13) O(1)—Na(1)—N(1)#3 87.62(15) O(1)#1—Na(1)—N(1)#3 114.29(16) N(1)—Na(1)—N(1)#3 82.51(13) N(1)#1—Na(1)—N(1)#3 177.1(2) N(1)#2—Na(1)—N(1)#3 94.6(2) O(1)—Na(1)—Na(1)#3 105.83(14) O(1)#1—Na(1)—Na(1)#3 105.82(14) N(1)—Na(1)—Na(1)#3 129.81(12) N(1)#1—Na(1)—Na(1)#3 129.81(12) N(1)#2—Na(1)—Na(1)#3 47.30(12) N(1)#3—Na(1)—Na(1)#3 47.30(12) O(1)—Na(1)—Na(1)#4 74.18(14) O(1)#1—Na(1)—Na(1)#4 74.17(14) N(1)—Na(1)—Na(1)#4 50.19(12) N(1)#1—Na(1)—Na(1)#4 50.19(12) N(1)#2—Na(1)—Na(1)#4 132.70(12) N(1)#3—Na(1)—Na(1)#4 132.70(12) Na(1)#3—Na(1)—Na(1)#4 179.998(1) O(3)#5—Na(2)—O(3) 180.0 .sup. O(3)#5—Na(2)—O(2)#6 87.51(15) O(3)—Na(2)—O(2)#6 92.49(15) O(3)#5—Na(2)—O(2)#3 92.49(15) O(3)—Na(2)—O(2)#3 87.51(15) O(2)#6—Na(2)—O(2)#3 180.0 .sup. O(3)#5—Na(2)—O(2)#5 100.60(16) O(3)—Na(2)—O(2)#5 79.40(16) O(2)#6—Na(2)—O(2)#5 94.58(14) O(2)#3—Na(2)—O(2)#5 85.42(14) O(3)#5—Na(2)—O(2) 79.40(16) O(3)—Na(2)—O(2) 100.60(16) O(2)#6—Na(2)—O(2) 85.42(14) O(2)#3—Na(2)—O(2) 94.58(14) O(2)#5—Na(2)—O(2) 180.0 .sup. O(3)#5—Na(2)—Na(2)#3 98.93(14) O(3)—Na(2)—Na(2)#3 81.07(14) O(2)#6—Na(2)—Na(2)#3 137.03(10) O(2)#3—Na(2)—Na(2)#3 42.97(10) O(2)#5—Na(2)—Na(2)#3 42.45(10) O(2)—Na(2)—Na(2)#3 137.55(10) O(3)#5—Na(2)—Na(2)#4 81.07(14) O(3)—Na(2)—Na(2)#4 98.93(14) O(2)#6—Na(2)—Na(2)#4 42.97(10) O(2)#3—Na(2)—Na(2)#4 137.02(10) O(2)#5—Na(2)—Na(2)#4 137.56(10) O(2)—Na(2)—Na(2)#4 42.45(10) Na(2)#3—Na(2)—Na(2)#4 180.0 .sup. O(3)#5—Na(2)—H(3A) 158.6(17) O(3)—Na(2)—H(3A) 21.4(17) O(2)#6—Na(2)—H(3A) 79.2(18) O(2)#3—Na(2)—H(3A) 100.8(18) O(2)#5—Na(2)—H(3A) 64.3(18) O(2)—Na(2)—H(3A) 115.7(18) Na(2)#3—Na(2)—H(3A) 80.3(18) Na(2)#4—Na(2)—H(3A) 99.7(18) C(1)—O(1)—Na(1) 123.5(4) C(1)—O(2)—Na(2)#4 130.2(4) C(1)—O(2)—Na(2) 122.4(4) Na(2)#4—O(2)—Na(2) 94.58(14) Na(2)—O(3)—H(3A) 95(4) Na(2)—O(3)—H(3B) 125(7) H(3A)—O(3)—H(3B) 99(8) C(2)—N(1)—C(3) 120.2(5) C(2)—N(1)—Na(1) 110.2(4) C(3)—N(1)—Na(1) 124.6(4) C(2)—N(1)—Na(1)#4 112.2(4) C(3)—N(1)—Na(1)#4 97.6(4) Na(1)—N(1)—Na(1)#4 82.51(13) C(3)—N(2)—H(2A) 114(4) C(3)—N(2)—H(2B) 118(4) H(2A)—N(2)—H(2B) 123(6) O(2)—C(1)—O(1) 125.1(6) O(2)—C(1)—C(2) 118.0(5) O(1)—C(1)—C(2) 116.9(5) N(1)—C(2)—C(3)#7 120.4(6) N(1)—C(2)—C(1) 116.9(5) C(3)#7—C(2)—C(1) 122.8(5) N(1)—C(3)—N(2) 116.7(5) N(1)—C(3)—C(2)#7 119.4(5) N(2)—C(3)—C(2)#7 123.8(6) Symmetry transformations used to generate equivalent atoms: #1−x, y, −z − 1/2 #2−x, y − 1, −z − 1/2 #3x, y − 1, z #4x, y + 1, z #5−x + 1/2, −y + 1/2, −z #6−x + 1/2, −y + 3/2, −z #7−x, −y + 2, −z
TABLE-US-00010 TABLE 4R Anisotropic displacement parameters (Å.sup.2 × 10.sup.3) for dm16105. The anisotropic displacement factor exponent takes the form: −2π.sup.2[h.sup.2 a*.sup.2U.sup.11 + . . . + 2 h k a* b* U.sup.12] U.sup.11 U.sup.22 U.sup.33 U.sup.23 U.sup.13 U.sup.12 Na(1) 23(2) 12(2) 19(2) 0 3(1) 0 Na(2) 19(2) 12(2) 24(2) 2(2) 5(2) −1(2) O(1) 21(2) 16(3) 17(2) −3(2) 3(2) 1(2) O(2) 20(3) 9(3) 22(2) 0(2) 2(2) 2(2) O(3) 20(3) 25(3) 25(3) −1(2) 7(2) −2(2) N(1) 17(3) 2(3) 22(3) 0(2) 4(2) −1(2) N(2) 20(3) 13(4) 19(3) −4(3) 4(3) 3(3) C(1) 16(4) 2(4) 22(4) 5(3) 3(3) −2(3) C(2) 19(3) 3(3) 20(2) 5(2) 1(2) −1(2) C(3) 19(3) 3(3) 20(2) 5(2) 1(2) −1(2)
TABLE-US-00011 TABLE 5R Hydrogen coordinates (×10.sup.4) and isotropic displacement parameters (Å.sup.2 × 10.sup.3) for dm16105. x y z U(eq) H(3A) 3150(40) 1200(200) 1860(50) 40(20) H(3B) 2660(50) 3100(300) 2230(70) 80(40) H(2A) −1120(30) 8900(170) −1960(40) 14(17) H(2B) −1510(20) 10860(180) −1240(40) 10(16)
TABLE-US-00012 TABLE 6R Torsion angles [°] for dm16105. O(1)#1—Na(1)—O(1)—C(1) 72.9(5) N(1)—Na(1)—O(1)—C(1) 20.0(5) N(1)#1—Na(1)—O(1)—C(1) 119.8(5) N(1)#2—Na(1)—O(1)—C(1) −156.9(5) N(1)#3—Na(1)—O(1)—C(1) −62.9(5) Na(1)#3—Na(1)—O(1)—C(1) −107.1(5) Na(1)#4—Na(1)—O(1)—C(1) 72.9(5) O(3)#5—Na(2)—O(2)—C(1) 56.5(4) O(3)—Na(2)—O(2)—C(1) −123.5(4) O(2)#6—Na(2)—O(2)—C(1) 144.8(5) O(2)#3—Na(2)—O(2)—C(1) −35.2(5) O(2)#5—Na(2)—O(2)—C(1) 8(7) Na(2)#3—Na(2)—O(2)—C(1) −35.2(5) Na(2)#4—Na(2)—O(2)—C(1) 144.8(5) O(3)#5—Na(2)—O(2)—Na(2)#4 −88.32(16) O(3)—Na(2)—O(2)—Na(2)#4 91.68(16) O(2)#6—Na(2)—O(2)—Na(2)#4 0.0.sup. O(2)#3—Na(2)—O(2)—Na(2)#4 180.0 .sup. O(2)#5—Na(2)—O(2)—Na(2)#4 −137(6) Na(2)#3—Na(2)—O(2)—Na(2)#4 180.0 .sup. O(1)—Na(1)—N(1)—C(2) −21.7(4) O(1)#1—Na(1)—N(1)—C(2) −176.9(4) N(1)#1—Na(1)—N(1)—C(2) −110.9(4) N(1)#2—Na(1)—N(1)—C(2) 69.1(4) N(1)#3—Na(1)—N(1)—C(2) 69.1(4) Na(1)#3—Na(1)—N(1)—C(2) 69.1(4) Na(1)#4—Na(1)—N(1)—C(2) −110.9(4) O(1)—Na(1)—N(1)—C(3) −176.7(5) O(1)#1—Na(1)—N(1)—C(3) 28.1(5) N(1)#1—Na(1)—N(1)—C(3) 94.1(5) N(1)#2—Na(1)—N(1)—C(3) −85.9(5) N(1)#3—Na(1)—N(1)—C(3) −85.9(5) Na(1)#3—Na(1)—N(1)—C(3) −85.9(5) Na(1)#4—Na(1)—N(1)—C(3) 94.1(5) O(1)—Na(1)—N(1)—Na(1)#4 89.24(16) O(1)#1—Na(1)—N(1)—Na(1)#4 −65.95(15) N(1)#1—Na(1)—N(1)—Na(1)#4 0.002(1) N(1)#2—Na(1)—N(1)—Na(1)#4 179.998(11) N(1)#3—Na(1)—N(1)—Na(1)#4 180.0 .sup. Na(1)#3—Na(1)—N(1)—Na(1)#4 180.0 .sup. Na(2)#4—O(2)—C(1)—O(1) 89.2(7) Na(2)—O(2)—C(1)—O(1) −42.1(8) Na(2)#4—O(2)—C(1)—C(2) −91.4(6) Na(2)—O(2)—C(1)—C(2) 137.3(5) Na(1)—O(1)—C(1)—O(2) 164.0(5) Na(1)—O(1)—C(1)—C(2) −15.3(8) C(3)—N(1)—C(2)—C(3)#7 −1.2(10) Na(1)—N(1)—C(2)—C(3)#7 −157.5(5) Na(1)#4—N(1)—C(2)—C(3)#7 112.5(5) C(3)—N(1)—C(2)—C(1) 179.8(5) Na(1)—N(1)—C(2)—C(1) 23.5(7) Na(1)#4—N(1)—C(2)—C(1) −66.5(6) O(2)—C(1)—C(2)—N(1) 172.0(5) O(1)—C(1)—C(2)—N(1) −8.6(9) O(2)—C(1)—C(2)—C(3)#7 −7.0(9) O(1)—C(1)—C(2)—C(3)#7 172.4(6) C(2)—N(1)—C(3)—N(2) 177.4(5) Na(1)—N(1)—C(3)—N(2) −30.0(8) Na(1)#4—N(1)—C(3)—N(2) 56.1(6) C(2)—N(1)—C(3)—C(2)#7 1.2(10) Na(1)—N(1)—C(3)—C(2)#7 153.9(4) Na(1)#4—N(1)—C(3)—C(2)#7 −120.0(5) Symmetry transformations used to generate equivalent atoms: #1−x, y, −z − 1/2 #2−x, y − 1, −z − 1/2 #3x, y − 1, z #4x, y + 1, z #5−x + 1/2, −y + 1/2, −z #6−x + 1/2, −y + 3/2, −z #7−x, −y + 2, −z
[0150] Various publications are referenced throughout this disclosure by Arabic numerals in brackets. A full citation corresponding to each reference number is listed below. The disclosures of these publications are herein incorporated by reference in their entireties.
REFERENCES
[0151] 1. Nally, J. V. Acute renal failure in hospitalized patients. Cleveland Clinic Journal of Medicine 2002, 69(7), 569-574. [0152] 2. C. A. Rabito, L. S. T. Fang, and A. C. Waltman. Renal function in patients at risk with contrast material-induced acute renal failure: Noninvasive real-time monitoring. Radiology 1993, 186, 851-854. [0153] 3. N. L. Tilney, and J. M. Lazarus. Acute renal failure in surgical patients: Causes, clinical patterns, and care. Surgical Clinics of North America 1983, 63, 357-377. [0154] 4. B. E. VanZee, W. E. Hoy, and J. R. Jaenike. Renal injury associated with intravenous pyelography in non-diabetic and diabetic patients. Annals of Internal Medicine 1978, 89, 51-54. [0155] 5. S. Lundqvist, G. Edbom, S. Groth, U. Stendahl, and S.-O. Hietala. Iohexol clearance for renal function measurement in gynecologic cancer patients. Acta Radiologica 1996, 37, 582-586. [0156] 6. P. Guesry, L. Kaufman, S. Orloff, J. A. Nelson, S. Swann, and M. Holliday. Measurement of glomerular filtration rate by fluorescent excitation of non-radioactive meglumine iothalamate. Clinical Nephrology 1975, 3, 134-138). [0157] 7. C. C. Baker et al. Epidemiology of Trauma Deaths. American Journal of Surgery 1980, 144-150. [0158] 8. R. G. Lobenhoffer et al. Treatment Results of Patients with Multiple Trauma: An Analysis of 3406 Cases Treated Between 1972 and 1991 at a German Level I Trauma Center. Journal of Trauma 1995, 38, 70-77. [0159] 9. J. Coalson, Pathology of Sepsis, Septic Shock, and Multiple Organ Failure. In New Horizons: Multiple Organ Failure, D. J. Bihari and F. B. Cerra, (Eds). Society of Critical Care Medicine, Fullerton, Calif., 1986, pp. 27-59. [0160] 10. F. B. Cerra, Multiple Organ Failure Syndrome. In New Horizons: Multiple Organ Failure, D. J Bihari and F. B. Cerra, (Eds). Society of Critical Care Medicine, Fullerton, Calif., 1989, pp. 1-24. [0161] 11. R. Muller-Suur, and C. Muller-Suur. Glomerular filtration and tubular secretion of MAG.sub.3 in rat kidney. Journal of Nuclear Medicine 1989, 30, 1986-1991). [0162] 12. P. D. Dollan, E. L. Alpen, and G. B. Theil. A clinical appraisal of the plasma concentration and endogenous clearance of creatinine. American Journal of Medicine 1962, 32, 65-79. [0163] 13. J. B. Henry (Ed). Clinical Diagnosis and Management by Laboratory Methods, 17th Edition, W.B. Saunders, Philadelphia, Pa., 1984. [0164] 14. F. Roch-Ramel, K. Besseghir, and II. Murer. Renal excretion and tubular transport of organic anions and cations. In Handbook of Physiology, Section 8, Neurological Physiology, Vol. II, E. E. Windhager, Editor, pp. 2189-2262. Oxford University Press: New York, 1992 [0165] 15. D. L. Nosco and J. A. Beaty-Nosco. Chemistry of technetium radiopharmaceuticals 1: Chemistry behind the development of technetium-99m compounds to determine kidney function. Coordination Chemistry Reviews 1999, 184, 91-123. [0166] 16. P. L. Choyke, H. A. Austin, and J. A. Frank. Hydrated clearance of gadolinium-DTPA as a measurement of glomerular filtration rate. Kidney International 1992, 41, 1595-1598. [0167] 17. N. Lewis, R. Kerr, and C. Van Buren. Comparative evaluation of urographic contrast media, inulin, and .sup.99mTc-DTPA clearance methods for determination of glomerular filtration rate in clinical transplantation. Transplantation 1989, 48, 790-796). [0168] 18. W. N. Tauxe. Tubular Function. In Nuclear Medicine in Clinical Urology and Nephrology, W. N. Tauxe and E. V. Dubovsky, Editors, pp. 77-105, Appleton Century Crofts: East Norwalk, 1985. [0169] 19. A. R. Fritzberg et al. Mercaptoacetylglycylglycyglycine. Journal of Nuclear Medicine 1986, 27, 111-120. [0170] 20. G. Ekanoyan and N. W. Levin. In Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification (K/DOQI). National Kidney Foundation: Washington, D.C. 2002, pp. 1-22. [0171] 21. Ozaki, H. et al. Sensitization of europium(III) luminescence by DTPA derivatives. Chemistry Letters 2000, 312-313. [0172] 22. Rabito, C. Fluorescent agents for real-time measurement of organ function. 2002; U.S. Pat. No. 6,440,389. [0173] 23. R. Rajagopalan, R. et al. Polyionic fluorescent bioconjugates as composition agents for continuous monitoring of renal function. In Molecular Imaging: Reporters, Dyes, Markers, and Instrumentation, A. Priezzhev, T. Asakura, and J. D. Briers, Editors, Proceedings of SPIE, 2000, 3924. [0174] 24. Dorshow, R. B. et al. Noninvasive renal function assessment by fluorescence detection. In Biomedical Optical Spectroscopy and Diagnostics, Trends in Optics and Photonics Series 22, E. M Sevick-Muraca, J. A. Izatt, and M. N. Ediger, Editors, pp. 54-56, Optical Society of America, Washington D.C., 1998. [0175] 25. Shirai, K. et al Synthesis and fluorescent properties of 2,5-diamino-3,6-dicyanopyrazine dyes. Dyes and Pigments 1998, 39(1), 49-68. [0176] 26. Kim, J. H. et al. Self-assembling of aminopyrazine fluorescent dyes and their solid state spectra. Dyes and Pigments 1998, 39(4), 341-357. [0177] 27. Barlin, G. B. The pyrazines. In The Chemistry of Heterocyclic Compounds. A. Weissberger and E. C.
[0178] Taylor, Eds. John Wiley & Sons, New York: 1982. [0179] 28. Donald, D. S. Synthesis of 3,5-diaminopyrazinoic acid from 3,5-diamino-2,6-dicyanopyrazine and intermediates. 1976; U.S. Pat. No. 3,948,895. [0180] 29. Donald, D. S. Diaminosubstituted dicyanopyrzines and process. 1974; U.S. Pat. No. 3,814,757. [0181] 30. Muller et al. Eds, Medical Optical Tomography, SPIE Volume IS11, 1993. [0182] 31. R. B. Dorshow et al. Non-Invasive Fluorescence Detection of Hepatic and Renal Function, Bull. Am. Phys. Soc. 1997, 42, 681. [0183] 32. R. B. Dorshow et al. Monitoring Physiological Function by Detection of Exogenous Fluorescent Contrast Agents. In Optical Diagnostics of Biological Fluids IV, A. Priezzhev and T. Asakura, Editors, Proceedings of SPIE 1999, 3599, 2-8).